Stockscreener 앱 받기
1.42
1.43%
0.02
전일 마감가:
$1.40
열려 있는:
$1.39
하루 거래량:
43,696
Relative Volume:
0.02
시가총액:
$3.87M
수익:
$644.60K
순이익/손실:
$-9.87M
주가수익비율:
-0.00169
EPS:
-837.9618
순현금흐름:
$-9.02M
1주 성능:
-5.96%
1개월 성능:
-15.98%
6개월 성능:
-74.78%
1년 성능:
-95.19%
1일 변동 폭
$1.38
$1.4429
1주일 범위
$1.38
$1.51
52주 변동 폭
$1.14
$74.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
1.41 | 3.87M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.43 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.99 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.49 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.35 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.20 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr 주식(BDRX)의 최신 뉴스
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa reports survival rates in glioblastoma study - Investing.com
Interim results for the six months ended June 30, 2024 - StockTitan
ADR Ratio Change - GlobeNewswire
Biodexa secures full access to cancer research grant - Investing.com
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Biodexa’s eRapa Shows Promise in FAP Treatment - TipRanks
PRFX Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune
Biodexa Pharma (BDRX) Stock Rallied 27% on Investor Interest - AskTraders.com
Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis - MarketBeat
BDRX News Today | Why did Biodexa Pharmaceuticals stock go down today? - MarketBeat
Biodexa Pharmaceuticals Announces Exercise of Warrants and Issue of Equity - Investing.com
Midatech Is Something To Keep An Eye On (NASDAQ:BDRX) - Seeking Alpha
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN
Biodexa Pharmaceuticals Plc Adr (BDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):